Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis

G. Saggese, A. M. Pasquino, S. Bertelloni, G. I. Baroncelli, R. Battini, I. Pucarelli, M. Segni, G. Franchi

Research output: Contribution to journalArticlepeer-review

Abstract

Growth hormone-insulin-like growth factor-I status and response to growth hormone therapy (0.6 IU/kg/week sc, six times a week for 12 months) were evaluated in 12 girls (chronological age 9.4 ± 1.6 years) suffering from central precocious puberty with growth velocity less than 4 cm/year and no substantial increase or decrease in predicted adult height during gonadotropin releasing hormone (Gn-RH) analogue treatment (D-Trp6-LH-RH, 60 μg/kg im/28 days). At baseline, large variations were observed in nocturnal growth hormone (GH) means (pathological values (<3.6 μg/l) 33.3%), stimulated levodopa GH peaks (pathological values (

Original languageEnglish
Pages (from-to)299-304
Number of pages6
JournalActa Paediatrica, International Journal of Paediatrics
Volume84
Issue number3
Publication statusPublished - 1995

Keywords

  • Central precocious puberty
  • Gn-RH analogue treatment
  • Growth hormone
  • Growth velocity
  • Predicted adult height

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis'. Together they form a unique fingerprint.

Cite this